Skip to main content

Table 2 Clinical and demographic features of RespondersT13 and NON-RespondersT13

From: Does MIDAS reduction at 3 months predict the outcome of erenumab treatment? A real-world, open-label trial

 

Total

RespondersT13

NON-RespondersT13

p-value

n

77

50

27

-

Age, (years, m ± sd)

49.8 ± 9.5

49.4 ± 9.4

50.6 ± 9.7

0.967

Females, n (%)

55 (71.4)

33 (66.0)

22 (81.5)

0.191

Age at headache onset (years, m ± sd)

14.5 ± 6.9

15.0 ± 7.3

13.6 ± 6.2

0.300

Years lived with migraine (years, m ± sd)

35.6 ± 10.8

34.8 ± 10.5

36.9 ± 11.2

0.701

Years lived with chronic migraine (years, m ± sd)

13.1 ± 10.3

12.6 ± 10.0

14.2 ± 12.6

0.424

Migraine with aura, n (%)

13 (16.9)

10 (20.0)

3 (11.1)

0.525

MOH, n (%)

71 (92.2)

40 (95.2)

31 (88.6)

0.402

Previous detoxification for MOH, n (%)

69 (89.6)

45 (90.0)

24 (88.9)

0.879

Preventive treatment

 Patients on preventive treatment at T0, n (%)

42 (54.5)

28 (56.0)

14 (51.9)

0.812

 Number of previously failed preventive treatments (m ± sd)

3.8 ± 1.2

3.7 ± 1.3

4.0 ± 1.0

0.439

 Previous BoNT-A treatment, n (%)

47 (61.0)

27 (54.0)

20 (74.1)

0.094

Classes of acute drugs

 NSAIDs, n (%)

12 (15.6)

7 (16.7)

5 (14.3)

0.408

 Triptans, n (%)

20 (26.0)

9 (21.4)

11 (31.4)

 Combination, n (%)

4 (5.2)

1 (2.4)

3 (8.6)

 Multiple drug classes, n (%)

41 (53.2)

25 (59.5)

16 (45.7)

Comorbidities

 Hypertension, n (%)

19 (24.7)

11 (26.2)

8 (22.9)

0.795

 Anxiety, n (%)

22 (28.6)

12 (28.6)

10 (28.6)

0.999

 Depression, n (%)

4 (5.2)

2 (4.8)

2 (5.7)

 Anxiety and depression, n (%)

18 (23.4)

10 (12.9)

8 (10.3)

 vInsomnia, n (%)

33 (42.9)

18 (42.9)

15 (42.9)

1.000

Migraine features at baseline

 Monthly headache days (m ± sd)

24.6 ± 4.8

24.3 ± 4.9

25.2 ± 4.6

0.545

 Monthly migraine days (m ± sd)

23.0 ± 5.1

22.9 ± 4.9

23.1 ± 5.4

0.861

 Monthly days of acute drugs intake (m ± sd)

20.8 ± 7.6

21.0 ± 7.3

20.3 ± 8.2

0.534

 Monthly doses of acute drugs intake (m ± sd)

34.7 ± 29.9

33.8 ± 28.6

36.3 ± 32.6

0.898

Questionnaires at baseline

 MIDAS (m ± sd)

77.5 ± 69.0

74.0 ± 70.7

84.0 ± 66.5

0.452

 Mean headache intensity (m ± sd)

8.0 ± 6.4

8.3 ± 7.9

7.5 ± 1.1

0.349

 HIT-6 (m ± sd)

66.8 ± 5.8

66.0 ± 5.7

68.3 ± 5.6

0.113

 ASC-12 (allodynia) (m ± sd)

6.4 ± 5.1

6.1 ± 5.5

6.8 ± 4.4

0.707

 MSQ (m ± sd)

34.4 ± 18.1

36.8 ± 16.0

29.7 ± 21.0

0.190

 General Health (0–100) (m ± sd)

54.4 ± 22.3

59.2 ± 19.4

45.6 ± 2 4.9

0.022

 HADS-A (m ± sd)

6.51 ± 4.03

6.0 ± 3.9

7.4 ± 4.1

0.079

 HADS-D (m ± sd)

6.39 ± 4.40

5.6 ± 4.3

7.8 ± 4.3

0.031

  1. Legend: RespondersT13: Patients with a MMDs reduction from baseline of at least 50% in the last 4 weeks of observation period (after 13 erenumab administrations). NON-RespondersT13: Patients with a MMDs reduction from baseline < 50% in the last 4 weeks of observation period (after 13 erenumab administrations).
  2. CM Chronic migraine, CM + MOH Chronic migraine and medication overuse headache, BoNT-A Onabotulinumtoxin-A, MIDAS MIgraine Disability Assessment, HIT-6 Headache Impact Test-6, ASC-12 Allodynia Symptoms Checlist, MSQ Migraine-Specific Quality of Life Questionnaire, HADS Hospital Anxiety and Depression Scale. Data are presented as means ± standard deviations (m ± sd) or absolute values (percentages).
Back to article page

The Journal of Headache and Pain

ISSN: 1129-2377

Contact us